Key result
Assessing the effects of new therapies on multiple clinical endpoints using the average Z score provides approximately double the power achievable by assessing the effects on dyspnea alone.
Why the study?
Does the average Z score method improve statistical power to detect therapeutic efficacy compared to assessing dyspnea alone in phase II acute heart failure trials?
Population
Simulated phase II acute heart failure clinical trials
Comparison
Global statistical methods assessing multiple… vs Assessing dyspnea alone or other statistical…
Authors
Loading...
May enable smaller phase II AHF trials; leaves open validation against clinical outcomes and regulatory standards.
Does the average Z score method improve statistical power to detect therapeutic efficacy compared to assessing dyspnea alone in phase II acute heart failure trials?
Using the average Z score to assess multiple clinical endpoints in phase II acute heart failure trials significantly increases statistical power, allowing for smaller sample sizes compared to single-endpoint assessments.
Sun et al. (2012) studied Acute heart failure. Average Z score method vs. Assessing dyspnea alone was evaluated on Power to detect therapeutic efficacy across multiple clinical endpoints. Assessing the effects of new therapies on multiple clinical endpoints using the average Z score provides approximately double the power achievable by assessing the effects on dyspnea alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: